Is bimekizumab a domestic drug or an imported drug?

Bimekizumab (Bimekizumab) is an imported original drug developed and produced by the Belgian pharmaceutical company UCB Inc. UCB Inc. is a leading global biopharmaceutical company that has long been focused on the research and development of innovative drugs in the fields of immunology, neuroscience and rare diseases. As one of UCB's core drugs in the field of immunology, bichizumab inherits the company's leading technology and research results in biopharmaceuticals.

Bichizumab is a humanized monoclonalIgG1 antibody with a dual-targeting mechanism. It mainly inhibits the activity of two cytokines, IL-17A and IL-17F, to reduce the overreaction of the immune system, thereby effectively alleviating immune-mediated inflammatory reactions. Its unique dual mechanism of action allows bicizumab to show significant efficacy in the treatment of immune diseases such as plaque psoriasis, especially in patients for whom other traditional treatments are ineffective.

As an original drug, the research and development of bicizumab took many years and involved a large number of clinical trials to ensure its efficacy and safety. Compared with traditional immunosuppressive agents, bichizumab has higher targeting and selectivity, and can act more precisely on specific molecules of the immune system, thereby effectively controlling the progression of the disease and reducing side effects. In addition, the effectiveness of bichizumab in treating psoriasis, ankylosing spondylitis and other diseases has been verified by multiple international clinical studies and has been widely recognized by the medical community.

Although the application of bicizumab is gradually promoted globally, in the Chinese market, the drug is still in the stage of imported drugs. Because it is an imported drug and there are currently no domestic generic drugs on the market, its price is relatively high and some patients may face financial pressure. As market demand increases, a generic version of the drug may be launched domestically in the future, thereby providing more patients with more price-competitive treatment options.

Reference materials:https://www.drugs.com/bimekizumab.html